210 related articles for article (PubMed ID: 18492783)
1. Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease.
Hinojosa J; Borrás-Blasco J; Maroto N; Rosique-Robles JD; Alos R; Casterá ME
Ann Pharmacother; 2008 Jul; 42(7):1130-3. PubMed ID: 18492783
[TBL] [Abstract][Full Text] [Related]
2. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
3. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
[TBL] [Abstract][Full Text] [Related]
5. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.
Emmert MY; Salzberg SP; Emmert LS; Behjati S; Plass A; Felix C; Falk V; Gruenenfelder J
Eur J Heart Fail; 2009 Nov; 11(11):1106-9. PubMed ID: 19875411
[TBL] [Abstract][Full Text] [Related]
6. [Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology].
Reinisch W; Haas T; Kaser A; Petritsch W; Vogelsang H; Feichtenschlager T; Novacek G; Siebert F; Tilg H; Knoflach P
Z Gastroenterol; 2009 Apr; 47(4):372-80. PubMed ID: 19358065
[TBL] [Abstract][Full Text] [Related]
7. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease.
Steenholdt C; Svenson M; Bendtzen K; Thomsen OØ; Brynskov J; Ainsworth MA
J Crohns Colitis; 2012 Feb; 6(1):108-11. PubMed ID: 22261535
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
Wyneski MJ; Green A; Kay M; Wyllie R; Mahajan L
J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
[TBL] [Abstract][Full Text] [Related]
9. A case of fistulizing Crohn's disease and erythema nodosum managed with adalimumab.
Quin A; Kane S; Ulitsky O
Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):278-81. PubMed ID: 18364718
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience.
Oussalah A; Babouri A; Chevaux JB; Stancu L; Trouilloud I; Bensenane M; Boucekkine T; Bigard MA; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2009 Feb; 29(4):416-23. PubMed ID: 19035976
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
Peyrin-Biroulet L; Laclotte C; Bigard MA
Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
Tonelli F; Giudici F; Asteria CR
Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
Riis A; Martinsen TC; Waldum HL; Fossmark R
Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
[TBL] [Abstract][Full Text] [Related]
14. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.
Russo EA; Iacucci M; Lindsay JO; Campbell S; Hart A; Hamlin J; Orchard T; Arebi N; Nightingale J; Jacyna MR; Gabe SM; O'Connor M; Harris AW; O'Morain C; Ghosh S
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):334-9. PubMed ID: 19528808
[TBL] [Abstract][Full Text] [Related]
15. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
[TBL] [Abstract][Full Text] [Related]
16. [The use of adalimumab in severe fistulising Crohn's disease].
Bang UC; Nielsen AM
Ugeskr Laeger; 2008 Jun; 170(25):2256. PubMed ID: 18565318
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
[TBL] [Abstract][Full Text] [Related]
18. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
[TBL] [Abstract][Full Text] [Related]
19. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults.
Colombel JF
Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):163-76. PubMed ID: 19072351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]